Can a Gene-Silencing drug tame a rare heart disease?
Disease control
Not yet recruiting
This trial tests an investigational medicine called ATR 1072 in adults with PRKAG2 syndrome, a genetic condition that causes abnormal heart muscle thickening and rhythm problems. The drug is designed to reduce the activity of the faulty PRKAG2 gene. Researchers are evaluating its…
Phase: PHASE1, PHASE2 • Sponsor: Atrium Therapeutics • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC